PhaseV is leveraging cutting-edge algorithms such as reinforcement learning and causal ML for adaptive trial design and closed-loop execution, in order to improve trial success rate while maximizing resource and time efficiency. Our novel methodology and advanced technology also enable the detection of hidden signals in data while analyzing clinical trial results and extracting actionable insights.
Employees: 11-50
Total raised: $15M
Investors 1
| Date | Name | Website |
| 13.11.2023 | LionBird | lionbird.c... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 31.10.2023 | - | $15M | - |
Mentions in press and media 5
| Date | Title | Description | Source |
| 07.11.2023 | 9xchange Biopharma Marketplace Partners with PhaseV to Bring... | The 9xchange platform releases drugs from owners who are unlikely to pursue them further, while prov... | aithority.... |
| 31.10.2023 | PhaseV Raises $15M for ML-Driven Clinical Trial Optimization | What You Should Know: PhaseV a pioneer in causal machine learning (ML) technology that optimizes cl... | hitconsult... |
| 24.10.2023 | PhaseV Raises $15M Funding | PhaseV, a Tel Aviv, Israel and Boston, MA-based company which specializes in causal machine learning... | finsmes.co... |
| 24.10.2023 | PhaseV reaps $15M in funding to streamline trial design with... | PhaseV, which uses machine learning to help design clinical trials, received a $15 million funding s... | fiercebiot... |
| 24.10.2023 | PhaseV Nabs $15M | BOSTON, MA, PhaseV a pioneer in causal machine learning (ML) technology that optimizes clinical tr... | vcnewsdail... |